Payment overview · 2025
General Payments
$792.22
24 reported records · 15 companies
Healthcare provider profile · identity verified
Hesham E Abdelrazek, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · PHOENIX, AZ · NPI 1841266681
Verified facts
What the public records show
CMS Open Payments records show Hesham E Abdelrazek, MD received $792.22 in general payments during 2025 across 24 reported records.
Paragonix Technologies, Inc. accounted for 33.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Cresemba, Prevymis.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Cresemba as an associated drug or biological on 2800 records involving 1563 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Cresemba by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PREVYMIS as an associated drug or biological on 2265 records involving 1245 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Prevymis by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GAMMAGARD LIQUID as an associated drug or biological on 29 records involving 8 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Gammagard Liquid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Paragonix Technologies, Inc. | Unresolved — no canonical attribution shown | $265.54 | 33.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $107.75 | 13.6% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $74.99 | 9.5% | 3 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $71.64 | 9.0% | 3 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $53.32 | 6.7% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $29.76 | 3.8% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $28.59 | 3.6% | 2 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $22.01 | 2.8% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $21.98 | 2.8% | 1 | 2025 |
| Invivyd Inc | Unresolved — no canonical attribution shown | $21.28 | 2.7% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $21.25 | 2.7% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $20.83 | 2.6% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $20.56 | 2.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.68 | 2.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.04 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $792.22 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BaroGuard Normalized: baroguard |
Device | Paragonix Technologies, Inc. | $265.54 | 2 | 2025 |
Source payment records
|
|||||
| LungGuard Normalized: lungguard |
Device | Paragonix Technologies, Inc. | $265.54 | 2 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $73.23 | 3 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $71.64 | 3 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $67.18 | 2 | 2025 |
Source payment records
|
|||||
| PREVYMIS Normalized: prevymis |
Drug | Merck Sharp & Dohme LLC | $54.05 | 2 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $53.32 | 1 | 2025 |
Source payment records
|
|||||
| EMBLAVEO Normalized: emblaveo |
Drug | ABBVIE INC. | $50.94 | 2 | 2025 |
Source payment records
|
|||||
| LIVTENCITY Normalized: livtencity |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $29.76 | 1 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $28.59 | 2 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $27.19 | 1 | 2025 |
Source payment records
|
|||||
| ZERBAXA Normalized: zerbaxa |
Drug | Merck Sharp & Dohme LLC | $24.82 | 1 | 2025 |
Source payment records
|
|||||
| Tyvaso Normalized: tyvaso |
Drug | United Therapeutics Corporation | $22.01 | 1 | 2025 |
Source payment records
|
|||||
| LIBTAYO Normalized: libtayo |
Biological | Regeneron Healthcare Solutions, Inc. | $21.98 | 1 | 2025 |
Source payment records
|
|||||
| PEMGARDA Normalized: pemgarda |
Biological | Invivyd Inc | $21.28 | 1 | 2025 |
Source payment records
|
|||||
| Cresemba Normalized: cresemba |
Drug | Astellas Pharma US Inc | $21.25 | 1 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $20.94 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $20.83 | 1 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $20.56 | 1 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $16.68 | 1 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Cresemba cresemba |
2025 | Cresemba | 2024 | 39 | exact normalized | Medicare Part D |
| PREVYMIS prevymis |
2025 | Prevymis | 2024 | 100 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Cresemba open payments reported associated product |
CMS Open Payments — General Payments 2800 supporting records · 1563 recipient NPIs · example record 1238560682 |
Cresemba · 2024 Exact normalized brand match · 1 Part D row |
39 | 11 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | PREVYMIS open payments reported associated product |
CMS Open Payments — General Payments 2265 supporting records · 1245 recipient NPIs · example record 1237992506 |
Prevymis · 2024 Exact normalized brand match · 1 Part D row |
100 | 20 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | GAMMAGARD LIQUID open payments reported associated product |
CMS Open Payments — General Payments 29 supporting records · 8 recipient NPIs · example record 1223786557 |
Gammagard Liquid · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Prednisone | Prednisone | 254 | 93 |
| Montelukast Sodium | Montelukast Sodium | 192 | 74 |
| Azithromycin | Azithromycin | 187 | 74 |
| Omeprazole | Omeprazole | 162 | 68 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 156 | 62 |
| Itraconazole | Itraconazole | 146 | 48 |
| Valganciclovir Hcl | Valganciclovir Hcl | 143 | 51 |
| Posaconazole | Posaconazole | 117 | 22 |
| Eliquis | Apixaban | 115 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 115 | 40 |
| Alendronate Sodium | Alendronate Sodium | 105 | 43 |
| Prevymis | Letermovir | 100 | 20 |
| Tacrolimus | Tacrolimus | 82 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 72 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 71 | 31 |
| Acyclovir | Acyclovir | 70 | 29 |
| Gabapentin | Gabapentin | 65 | 31 |
| Furosemide | Furosemide | 48 | 30 |
| Atovaquone | Atovaquone | 46 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 42 | 19 |
| Cresemba | Isavuconazonium Sulfate | 39 | 11 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 39 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 37 | 11 |
| Amlodipine Besylate | Amlodipine Besylate | 35 | 14 |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 34 | suppressed |
| Levofloxacin | Levofloxacin | 32 | 29 |
| Octagam | Immun Globg(Igg)/Malt/Iga Ov50 | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 30 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 28 | 11 |
| Amoxicillin | Amoxicillin | 24 | 14 |
| Valacyclovir | Valacyclovir Hcl | 22 | 19 |
| Carvedilol | Carvedilol | 20 | suppressed |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 12 |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Prolastin C | Alpha-1-Proteinase Inhibitor | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 11 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $792.22 · 24 records | Paragonix Technologies, Inc. | AVYCAZ, Arikayce, BaroGuard, Brinsupri, Cresemba, DALVANCE, DUPIXENT, EMBLAVEO, FASENRA, JASCAYD, KEYTRUDA, LIBTAYO, LIVTENCITY, LungGuard, Ohtuvayre, PEMGARDA, PREVYMIS, Tyvaso, UPTRAVI, Vest Therapy Und, ZERBAXA | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Cresemba play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error